Aptuit, LLC today announced that it has acquired Exquiron Biotech AG to meet customer demand for fully integrated outsourced discovery services. Exquiron is a leading specialist Contract Research Organization dedicated to early phase drug discovery solutions.
Located near Basel, Switzerland, Exquiron offers industry leading expertise in assay development for hit finding and profiling purposes, high throughput screening, selectivity testing and hit characterization. These services are complemented by an extensive library collection of lead like compounds, as well as deep scientific knowledge in compound selection and Structure Activity Relationship (SAR) expansion across a broad range of targets in multiple therapeutic areas.
Dr. Jonathan Goldman, Chief Executive Officer of Aptuit stated, “Aptuit specializes in the discovery of small molecules across a wide range of therapeutic areas including neuroscience, oncology, infectious disease, inflammation, respiratory and others. The acquisition of Exquiron broadens our scientific excellence in advanced integrated discovery by incorporating capabilities in early discovery. In particular, we are thrilled to enhance our hit identification, validation, and expansion services. We can now offer uninterrupted and very high quality delivery of a research program from target to high quality candidate nomination. We expect our customers to benefit from improved probability of candidate nomination, with reductions in time and cost.
Customers value our unique capabilities in integrated discovery and integrated development. We are delighted to combine our core scientific expertise in discovery with the early discovery capabilities of our Exquiron colleagues.”
Dr. Goldman explained that Aptuit’s best in class integrated discovery solutions are unique in the marketplace.
“Our company is experiencing increased demand for integrated services from gene up to candidate nomination, and from candidate to IND. We are delighted to respond by expanding our capabilities”.
Dr. Stephan Fasler, CEO and founder of Exquiron added, “We are excited to join Aptuit, a highly respected leader in the discovery and development CRO sector. Our customers can now combine our expertise in assay development and high throughput screening with the ability to translate seamlessly to candidate nomination and IND filing. Exquiron and Aptuit share a culture and commitment to scientific excellence, making this a very good fit”
Source: Aptuit
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
